Edward M. Wolin

14.6k total citations · 4 hit papers
135 papers, 7.3k citations indexed

About

Edward M. Wolin is a scholar working on Epidemiology, Oncology and Neurology. According to data from OpenAlex, Edward M. Wolin has authored 135 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Epidemiology, 115 papers in Oncology and 87 papers in Neurology. Recurrent topics in Edward M. Wolin's work include Neuroendocrine Tumor Research Advances (123 papers), Lung Cancer Research Studies (103 papers) and Neuroblastoma Research and Treatments (87 papers). Edward M. Wolin is often cited by papers focused on Neuroendocrine Tumor Research Advances (123 papers), Lung Cancer Research Studies (103 papers) and Neuroblastoma Research and Treatments (87 papers). Edward M. Wolin collaborates with scholars based in United States, France and Germany. Edward M. Wolin's co-authors include Marianne Pavel, Kjell Öberg, Jaume Capdevila, James C. Yao, Eric Van Cutsem, David Lebwohl, Timothy J. Hobday, Philippe Ruszniewski, Paola Tomassetti and Martyn Caplin and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Edward M. Wolin

128 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

2011 2.1k citations James C. Yao, Manisha H. Shah et al. New England Journal of Medicine profile →
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

2014 1.3k citations Martyn Caplin, Marianne Pavel et al. New England Journal of Medicine profile →
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

2011 767 citations Marianne Pavel, Robert Winkler et al. profile →
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With ¹⁷⁷Lu-Dotatate in the Phase III NETTER-1 Trial

2018 272 citations Jonathan Strosberg, Edward M. Wolin et al. profile →

Peers

Countries citing papers authored by Edward M. Wolin

Since Specialization

Citations

This map shows the geographic impact of Edward M. Wolin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward M. Wolin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward M. Wolin more than expected).

Fields of papers citing papers by Edward M. Wolin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward M. Wolin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward M. Wolin. The network helps show where Edward M. Wolin may publish in the future.

Co-authorship network of co-authors of Edward M. Wolin

This figure shows the co-authorship network connecting the top 25 collaborators of Edward M. Wolin. A scholar is included among the top collaborators of Edward M. Wolin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward M. Wolin. Edward M. Wolin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses 2024 ·Annals of Oncology ·Jennifer A. Chan, Susan M. Geyer, Tyler Zemla, Michael V. Knopp, Spencer C. Behr, (unknown), Jared D. Acoba, Ardaman Shergill, Edward M. Wolin, Þorvarður R. Hálfdánarson, Bhavana Konda, Nikolaos A. Trikalinos, Shagufta Shaheen, (unknown), (unknown), (unknown), Elise C. Kohn, (unknown), Eileen M. O’Reilly, Jeffrey A. Meyerhardt	0
2	LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET) 2023 ·Annals of Oncology ·Jennifer A. Chan, Susan M. Geyer, (unknown), Michael V. Knopp, Spencer C. Behr, Tyler Zemla, Jared D. Acoba, Ardaman Shergill, Edward M. Wolin, Þorvarður R. Hálfdánarson, Nikolaos A. Trikalinos, Bhavana Konda, (unknown), (unknown), (unknown), Elise C. Kohn, Matthew H. Kulke, Eileen M. O’Reilly, Jeffrey A. Meyerhardt	18
3	QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors 2018 ·Pancreas ·Jonathan Strosberg, Edward M. Wolin, Beth Chasen, (unknown), David Bushnell, Martyn Caplin, Richard P. Baum, Pamela L. Kunz, Timothy J. Hobday, (unknown), Kjell Öberg, Maribel Lopera Sierra, Philippe Ruszniewski, (unknown)	3
4	NETTER-1 Phase III Trial : Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors 2017 ·Neuroendocrinology ·(unknown), Edward M. Wolin, Beth Chasen, M. Kulke, David Bushnell, (unknown), R. P. Baum, Pamela L. Kunz, Timothy J. Hobday, (unknown), Kjell Öberg, (unknown), D. J. Kwekkeboom, (unknown), E. P. Krenning	2
5	Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension 2017 ·Annals of Oncology ·Jarosław B. Ćwikła, Edward M. Wolin, Marianne Pavel, Alexandria T. Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Jaume Capdevila, Guido Rindi, Catherine Lombard‐Bohas, (unknown), (unknown), Philippe Ruszniewski, Martyn Caplin	2
6	Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors 2017 ·Clinical Nuclear Medicine ·(unknown), (unknown), (unknown), Edward M. Wolin, Thomas M. O’Dorisio, David Ranganathan, Izabela Tworowska, Jonathan Strosberg, Ebrahim S. Delpassand	65
7	Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States 2016 ·Medicine ·Li Zhu, Laura H. Tang, Xinwei Qiao, Edward M. Wolin, Nicholas N. Nissen, Deepti Dhall, Jie Chen, Lin Shen, Yihebali Chi, Yaozong Yuan, Qiwen Ben, Bin Lv, Yaru Zhou, Chunmei Bai, (unknown), (unknown), (unknown), Run Yu, Yuan‐Jia Chen	49
8	ORAL02.02: Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis 2016 ·Journal of Thoracic Oncology ·James C. Yao, Nicola Fazio, Roberto Buzzoni, Gianfranco Delle Fave, Margot Tesselaar, Edward M. Wolin, Eric Van Cutsem, Paola Tomassetti, Jonathan Strosberg, Maurizio Voi, Lida Pacaud, Antonia Ridolfi, Simron Singh, Marianne Pavel, Matthew H. Kulke	2
9	Design of a phase 3, international multicenter, prospective, randomized, double-blind, placebo controlled study assessing the efficacy and safety of lanreotide depot 120 mg in patients with well-differentiated, advanced typical and atypical lung neuroendocrine tumors (NETs) 2016 ·Journal of Thoracic Oncology ·Diane Reidy‐Lagunes, Edward M. Wolin, Susan Pitman Lowenthal, D. F. Cox, Matthew H. Kulke	1
10	Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT study 2016 ·Annals of Oncology ·Edward M. Wolin, George A. Fisher, Pamela L. Kunz, (unknown), Susan Pitman Lowenthal, Beloo Mirakhur, Rodney F. Pommier, Montaser Shaheen, A Vinik	1
11	Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung 2016 ·CHEST Journal ·Edward M. Wolin	34
12	134O RADIANT-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (NET) of the lung or gastrointestinal (GI) tract 2015 ·Annals of Oncology ·James C. Yao, Simron Singh, Edward M. Wolin, Maurizio Voi, Lida Pacaud, Jeremie Lincy, (unknown), Juan W. Valle, Eric Van Cutsem, Yoshifumi Shimada, Do‐Youn Oh	2
13	Consensus on biomarkers for neuroendocrine tumour disease 2015 ·The Lancet Oncology ·Kjell Öberg, Irvin M. Modlin, Wouter W. de Herder, Marianne Pavel, David S. Klimstra, Andrea Frilling, David C. Metz, Anthony P. Heaney, Dik J. Kwekkeboom, Jonathan Strosberg, T Meyer, Steven F. Moss, Kay Washington, Edward M. Wolin, Eric Liu, James R. Goldenring	206
14	Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors breakdown → 2014 ·New England Journal of Medicine ·Martyn Caplin, Marianne Pavel, Jarosław B. Ćwikła, Alexandria T. Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M. Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley, Séverine Martinez, Joëlle Blumberg, Philippe Ruszniewski	1286
15	A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs 2014 ·Pancreas ·Edward M. Wolin, Barbara Jarząb, Barbro Eriksson, Thomas Walter, Christos Toumpanakis, Michael A. Morse, Paola Tomassetti, Matthias M. Weber, David R. Fogelman, John Ramage, Donald Poon, (unknown), Michelle Hudson, (unknown), Janice L. Pasieka, Abakar Mahamat, Fredrik Swahn, John Newell‐Price, (unknown), Kjell Öberg	2
16	Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors 2014 ·Pancreas ·Ebrahim S. Delpassand, Amin Samarghandi, Sara Zamanian, Edward M. Wolin, (unknown), Gregory D. Espenan, Jack L. Erion, Thomas M. O’Dorisio, Larry K. Kvols, (unknown), (unknown), (unknown), Eric P. Krenning, Alireza Mojtahedi	108
17	Treatment of Pancreatic Neuroendocrine Tumors (pNET) With Everolimus: Improved Progression-Free Survival Compared With Placebo (RADIANT-3) 2011 ·Pancreas ·Manisha H. Shah, Kjell Öberg, Tetsuhide Ito, Catherine Lombard‐Bohas, Edward M. Wolin, Eric Van Cutsem, Carolin Sachs, Robert Winkler, Jeremie Lincy, (unknown), James C. Yao	1
18	Everolimus for Advanced Pancreatic Neuroendocrine Tumors breakdown → 2011 ·New England Journal of Medicine ·James C. Yao, Manisha H. Shah, Tetsuhide Ito, C. Lombard Bohas, Edward M. Wolin, Eric Van Cutsem, Timothy J. Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Marianne Pavel, Sakina Hoosen, T Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg	2078
19	Morphologic Features of Carcinoid Heart Disease as Assessed by Three‐Dimensional Transesophageal Echocardiography 2010 ·Echocardiography ·(unknown), Robert J. Siegel, Edward M. Wolin, Run Yu, Alfredo Trento, Takahiro Shiota, Kirsten Tolstrup, Daniel Luthringer, Swaminatha V. Gurudevan	4
20	A Multiinstitutional Evaluation of the Analgesic Efficacy and Safety of Ketorolac Tromethamine, Acetaminophen plus Codeine, and Placebo in Cancer Pain 1990 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Robert W. Carlson, (unknown), (unknown), Peter D. Eisenberg, Phyllis Ager Mowry, Edward M. Wolin	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact